EcoDrugPlus

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSTTRG00000006154
Gene Symbol: GRIK2
1 Cross references
331 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSTTRG00000002432
Gene Symbol: GRIK3
1 Cross references
256 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSTTRG00000012094
Gene Symbol: GRIK4
1 Cross references
260 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSTTRG00000008314
Gene Symbol: GRIK5
1 Cross references
302 Possible Orthologues:

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSTTRG00000001435
Gene Symbol: GRM2
1 Cross references
276 Possible Orthologues:

Glutamate Metabotropic Receptor 3

Ensembl ID : ENSTTRG00000013480
Gene Symbol: GRM3
1 Cross references
215 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSTTRG00000006581
Gene Symbol: GRM4
1 Cross references
272 Possible Orthologues:

Glutamate Metabotropic Receptor 5

Ensembl ID : ENSTTRG00000002975
Gene Symbol: GRM5
1 Cross references
272 Possible Orthologues:

Glutaminase

Ensembl ID : ENSTTRG00000001131
Gene Symbol: GLS
1 Cross references
302 Possible Orthologues:

Glycogen Synthase Kinase 3 Alpha

Ensembl ID : ENSTTRG00000008338
Gene Symbol: GSK3A
1 Cross references
260 Possible Orthologues:

Gonadotropin Releasing Hormone Receptor

Ensembl ID : ENSTTRG00000007811
Gene Symbol: GNRHR
3 Cross references
96 Possible Orthologues:

Growth Hormone Releasing Hormone Receptor

Ensembl ID : ENSTTRG00000000343
Gene Symbol: GHRHR
1 Cross references
191 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).